Van Diest Capital’s Novo Nordisk NVO Stock Holding History

Van Diest Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,958	Closed	-$219K	–	212
2026 Q1	$219K	Buy	+5,958	New	+$282K	0.17%	165

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Van Diest Capital's NVO Position: Q2 2026 in Review

Van Diest Capital sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 5,958 shares — an estimated $219K sold.

Van Diest Capital first reported a position in NVO in Q1 2026 and held it in 1 quarter. The position peaked at $219K in Q1 2026. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Van Diest Capital reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
Van Diest Capital sold 5,958 Novo Nordisk shares in Q2 2026, an estimated $219K.
Van Diest Capital first reported a position in Novo Nordisk in Q1 2026 and held it in 1 quarter.
Van Diest Capital's Novo Nordisk position peaked at $219K in Q1 2026.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Van Diest Capital's 13F filing for Q2 2026, filed 4 Aug 2026.